Guanglin Xiao, Taiyu He, Biqiong Zhang, Ziqiao Yang, Ning Ling, Min Chen, Dazhi Zhang, Peng Hu, Gaoli Zhang, Mingli Peng, Dachuan Cai, Hong Ren
{"title":"Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis.","authors":"Guanglin Xiao, Taiyu He, Biqiong Zhang, Ziqiao Yang, Ning Ling, Min Chen, Dazhi Zhang, Peng Hu, Gaoli Zhang, Mingli Peng, Dachuan Cai, Hong Ren","doi":"10.3389/ijph.2024.1605295","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This review aimed to assess the safety and efficacy of SARS-CoV-2 vaccines in patients with chronic liver disease (CLD).</p><p><strong>Methods: </strong>Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science were searched from 2020 to 2024. Data was extracted following Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. The random-effects model (when I<sup>2</sup> ≥ 50%) or fixed effect model (I<sup>2</sup> < 50%) was used.</p><p><strong>Results: </strong>29 studies were included in this review. Compared to healthy controls (HCs), patients with CLD had a higher incidence of mild adverse events (RR = 1.60, <i>p</i> < 0.001), while the incidence of severe adverse events was similar (RR = 1.08, <i>p</i> = 0.92). Seropositivity rates of three antibodies in patients were lower than in HCs [neutralizing antibody (RR = 0.86, <i>p</i> = 0.002), anti-spike antibody (RR = 0.97, <i>p</i> = 0.06) and anti-receptor binding domain antibody (RR = 0.95, <i>p</i> = 0.04)]. Compared to unvaccinated patients, vaccinated patients had lower rates of SARS-CoV-2 infection, hospitalization and death (<i>p</i> ≤ 0.05).</p><p><strong>Conclusion: </strong>SARS-CoV-2 vaccines showed good safety and efficacy in CLD patients, but antibody response appeared to be decreased. Therefore, SARS-CoV-2 vaccines and booster doses should be given priority in this vulnerable population.</p>","PeriodicalId":14322,"journal":{"name":"International Journal of Public Health","volume":"69 ","pages":"1605295"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617177/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ijph.2024.1605295","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This review aimed to assess the safety and efficacy of SARS-CoV-2 vaccines in patients with chronic liver disease (CLD).
Methods: Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science were searched from 2020 to 2024. Data was extracted following Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. The random-effects model (when I2 ≥ 50%) or fixed effect model (I2 < 50%) was used.
Results: 29 studies were included in this review. Compared to healthy controls (HCs), patients with CLD had a higher incidence of mild adverse events (RR = 1.60, p < 0.001), while the incidence of severe adverse events was similar (RR = 1.08, p = 0.92). Seropositivity rates of three antibodies in patients were lower than in HCs [neutralizing antibody (RR = 0.86, p = 0.002), anti-spike antibody (RR = 0.97, p = 0.06) and anti-receptor binding domain antibody (RR = 0.95, p = 0.04)]. Compared to unvaccinated patients, vaccinated patients had lower rates of SARS-CoV-2 infection, hospitalization and death (p ≤ 0.05).
Conclusion: SARS-CoV-2 vaccines showed good safety and efficacy in CLD patients, but antibody response appeared to be decreased. Therefore, SARS-CoV-2 vaccines and booster doses should be given priority in this vulnerable population.
期刊介绍：
The International Journal of Public Health publishes scientific articles relevant to global public health, from different countries and cultures, and assembles them into issues that raise awareness and understanding of public health problems and solutions. The Journal welcomes submissions of original research, critical and relevant reviews, methodological papers and manuscripts that emphasize theoretical content. IJPH sometimes publishes commentaries and opinions. Special issues highlight key areas of current research. The Editorial Board''s mission is to provide a thoughtful forum for contemporary issues and challenges in global public health research and practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
